PTSD symptom reports of patients evaluated for the New Mexico Medical Cannabis Program.
George Greer, Charles S. Grob, Adam L. Halberstadt
Journal of Psychoactive Drugs January 1, 2014 DOI: 10.1080/02791072.2013.873843 (opens in new tab) via PubMed
Summary
AI-generated from the abstractGreater than 75% reduction in Clinician Administered PTSD Scale (CAPS) symptom scores was reported when patients were using cannabis compared to when they were not, based on a retrospective chart review of 80 patients applying to the New Mexico Medical Cannabis Program from 2009 to 2011. Cannabis is associated with reductions in PTSD symptoms in some patients, and prospective, placebo-controlled study is needed to determine efficacy.
Study at a glance
| Characteristics | Retrospective chart review Placebo-controlled Peer reviewed |
|---|---|
| Sample size | 80 |
| Population | Patients applying to the New Mexico Medical Cannabis Program from 2009 to 2011 |
| Intervention | cannabis |
| Key finding | Greater than 75% reduction in CAPS symptom scores was reported when patients were using cannabis compared to when they were not. |
Abstract
New Mexico was the first state to list post-traumatic stress disorder (PTSD) as a condition for the use of medical cannabis. There are no published studies, other than case reports, of the effects of cannabis on PTSD symptoms. The purpose of the study was to report and statistically analyze psychometric data on PTSD symptoms collected during 80 psychiatric evaluations of patients applying to the New Mexico Medical Cannabis Program from 2009 to 2011. The Clinician Administered Posttraumatic Scale for DSM-IV (CAPS) was administered retrospectively and symptom scores were then collected and compared in a retrospective chart review of the first 80 patients evaluated. Greater than 75% reduction in CAPS symptom scores were reported when patients were using cannabis compared to when they were not. Cannabis is associated with reductions in PTSD symptoms in some patients, and prospective, placebo-controlled study is needed to determine efficacy of cannabis and its constituents in treating PTSD.